Clinical trials: Solid Tumor
Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
This phase II trial tests how well CPI-613 (devimistat) in combination with hydroxychloroquine (HCQ) and 5-fluorouracil (5-FU) or gemcitabine works in patients with solid tumors that may have spread from where they first started…
- Conditions
- Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Lung Adenocarcinoma
- Trial name
- NCT05733000
- Testing
- Biospecimen Collection, Computed Tomography, Devimistat
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Northwestern University
Solid Tumor
Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody
The purpose of this study is to assess the safety and tolerability of Hu5F9-G4 in participants with solid tumors.
- Trial name
- NCT02216409
- Testing
- Hu5F9-G4
- Where
- 6 sites in United States
- Volunteers
- 88 people
- Sponsor
- Gilead Sciences
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00004057
- Testing
- L-778,123, paclitaxel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neoplasms
GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1)
This is a first time in human (FTIH), open-label, non-randomized, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary clinical activity of GSK3174998…
- Trial name
- NCT02528357
- Testing
- GSK3174998, Pembrolizumab
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 141 people
- Sponsor
- GlaxoSmithKline
Solid Tumor, Pancreatic Adenocarcinoma
A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors
A first-in-human open-label, Phase I/II study to evaluate the safety, tolerability, MTD/RP2D, PK, and preliminary efficacy of OBI-3424 administered as a single agent.
- Trial name
- NCT03592264
- Testing
- OBI-3424
- Where
- 5 sites in United States
- Volunteers
- 68 people
- Sponsor
- OBI Pharma, Inc
Carcinoma, Renal Cell
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
Phase II, multi-center, two-stage study utilising a randomised discontinuation design to evaluate the safety and efficacy of GW786034 (pazopanib) in adult subjects with locally recurrent or metastatic clear-cell Renal Cell…
- Trial name
- NCT00244764
- Testing
- GW786034
- Where
- 45 sites in United States, Australia and 6 more
- Volunteers
- 225 people
- Sponsor
- GlaxoSmithKline
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study
This clinical trial tests the impact of a culturally-tailored home-based physical activity program on physical fitness in Hispanic or Latino/Latina adolescent and young adult (AYA) childhood cancer survivors.
- Trial name
- NCT06410209
- Testing
- Discussion, Goal Setting, Interview
- Where
- 77 sites in United States, Puerto Rico
- Volunteers
- 190 people
- Sponsor
- Children's Oncology Group
Breast Carcinoma, Esophageal Carcinoma
Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
This study collects information on the side effects of proton therapy and detailed information on the proton therapy treatment plan itself.
- Conditions
- Breast Carcinoma, Esophageal Carcinoma, Genitourinary System Carcinoma, Head and Neck Carcinoma
- Trial name
- NCT00991094
- Testing
- Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced or Metastatic Solid Tumors
A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors
TAK-981 is being tested in combination with pembrolizumab to treat participants who have select advanced or metastatic solid tumors.
- Trial name
- NCT04381650
- Testing
- TAK-981, Pembrolizumab
- Where
- 52 sites in United States, Brazil and 7 more
- Volunteers
- 161 people
- Sponsor
- Takeda
Solid Tumor
A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors
The proposed clinical study is a Phase 1/2a trial to investigate the safety, tolerability, pharmacokinetics and clinical activity of anti-HLA-G CAR-T cells IVS-3001 administered to subjects with previously treated, locally…
- Trial name
- NCT05672459
- Testing
- Single Injection of IVS-3001- Anti - HLA-G CAR-T cells, Fludarabine phosphate, Cyclophosphamide
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Malignancies, Lymphoma
Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component)
This is a dose escalation study of CS-1008 (humanized anti-DR5 antibody) to determine the recommended Phase 2 dose and the maximum tolerated dose.
- Trial name
- NCT00320827
- Testing
- CS-1008 (humanized anti-DR5 antibody)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Daiichi Sankyo
Colorectal Neoplasms, Stomach Neoplasms
Proteomic Analysis of HLA Complex in Solid Cancers: Breast, Ovary, Colon, Rectum, Stomach, and Pancreas
The purpose of this study is to evaluate the presence of proteins in solid tumors which may lead to an immune response
- Conditions
- Colorectal Neoplasms, Stomach Neoplasms, Pancreatic Neoplasms, Breast Neoplasms
- Trial name
- NCT00419627
- Where
- Israel
- Volunteers
- 160 people
- Sponsor
- Hillel Yaffe Medical Center
Solid Tumors
Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients
The goal of this clinical research study is to find the highest safe dose of the drug Velcade (bortezomib) that can be given together with gemcitabine and pegylated liposomal doxorubicin (Doxil) in the treatment of advanced…
- Trial name
- NCT00500422
- Testing
- Doxil, Gemcitabine, Velcade
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Tumor
Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
The primary purpose of this study is to assess the safety and tolerability of RP-6306 with FOLFIRI in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD), identify a recommended phase 2 dose…
- Trial name
- MINOTAUR (NCT05147350)
- Testing
- RP-6306 (oral PKMYT1 inhibitor)
- Where
- 9 sites in United States, Canada and 2 more
- Volunteers
- 38 people
- Sponsor
- Debiopharm International SA
Cancer of Liver, Cancer of Pancreas
Effects of Dexmedetomidine During IRE Procedures for Solid Tumours
The purpose of the study is to evaluate effects of dexmedetomidine on anaesthesia during IRE procedures for solid tumours
- Trial name
- NCT02044224
- Testing
- Dexmedetomidine
- Where
- Sweden
- Volunteers
- 30 people
- Sponsor
- Uppsala University Hospital
Solid Tumors
Study of AUBE00 in Patients With Solid Tumors
This is a first-in-human, Phase I, open-label, multicenter, multinational study, designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and anti-tumor activity of AUBE00 in…
- Trial name
- NCT07030959
- Testing
- AUBE00, Cetuximab
- Where
- 5 sites in United States, Japan
- Volunteers
- 130 people
- Sponsor
- Chugai Pharmaceutical
Unspecified Adult Solid Tumor, Protocol Specific
BMS-188797 and Carboplatin in Treating Patients With Advanced Nonhematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006086
- Testing
- BMS-188797, carboplatin
- Where
- United States
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Nasopharyngeal Carcinoma (NPC), Solid Tumors
A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid Tumors
This Phase Ib/II study is a clinical trial to evaluate the efficacy and safety of BL-M08D1 for Injection in patients with recurrent or metastatic nasopharyngeal carcinoma and other solid tumors.
- Trial name
- NCT07818486
- Testing
- BL-M08D1
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Solid Tumor Cancer, PDAC
IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors
This is a multicenter, open-label, Phase Ib/II clinical study. The study includes Phase Ib-Dose Exploration Stage and Phase II - Efficacy Exploration and Determination Stage.
- Trial name
- NCT07441174
- Testing
- IN10018 in combination with RNK08954
- Where
- 14 sites in China
- Volunteers
- 92 people
- Sponsor
- InxMed (Shanghai) Co., Ltd.
Solid Tumor, Advanced Solid Tumor
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
This study consists of a Dose-Escalation stage and a Dose Expansion stage. The primary purpose of the dose escalation stage is to determine the maximum tolerated dose (MTD) and/or recommended dosage(s) for expansion (RDE[s]); and…
- Conditions
- Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor, Immune Sensitive Tumor
- Trial name
- NCT06952010
- Testing
- XB628, Zanzalintinib
- Where
- 11 sites in United States
- Volunteers
- 303 people
- Sponsor
- Exelixis